{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:30:20Z","timestamp":1790116220145,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10620-023-08060-7","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T14:02:15Z","timestamp":1691157735000},"page":"3994-4000","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn\u2019s Perianal Fistulae"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2401-2685","authenticated-orcid":false,"given":"Laura","family":"Maas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivy","family":"Cusumano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Spartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reezwana","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lazarev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Melia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin","family":"Selaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkeley","family":"Limketkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Parian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"8060_CR1","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1093\/ecco-jcc\/jjx180.915","volume":"12","author":"WY Mak","year":"2018","unstructured":"Mak WY, Mak OS, Lee CK et al. Significant medical and surgical morbidity in perianal Crohn\u2019s disease: results from a territory-wide study. J. Crohn\u2019s Colitis. 2018;12:1392\u20131398.","journal-title":"J. Crohn's Colitis."},{"key":"8060_CR2","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.3748\/wjg.v24.i42.4821","volume":"24","author":"J Panes","year":"2018","unstructured":"Panes J, Reinisch W, Rupniewska E et al. Burden and outcomes for complex perianal fistulas in Crohn\u2019s disease: systematic review. World J. Gastroenterol. 2018;24:4821\u20134834.","journal-title":"World J. Gastroenterol."},{"key":"8060_CR3","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/apt.13970","volume":"45","author":"AJ Yarur","year":"2017","unstructured":"Yarur AJ, Kanagala V, Stein DJ et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn\u2019s disease. Aliment. Pharmacol. Ther. 2017;45:933\u2013940.","journal-title":"Aliment. Pharmacol. Ther."},{"key":"8060_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1053\/gast.2002.32362","volume":"122","author":"DA Schwartz","year":"2002","unstructured":"Schwartz DA, Loftus EV, Tremaine WJ et al. The natural history of fistulizing Crohn\u2019s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875\u2013880.","journal-title":"Gastroenterology."},{"key":"8060_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12955-020-01622-7","volume":"18","author":"SO Adegbola","year":"2020","unstructured":"Adegbola SO, Dibley L, Sahnan K et al. Burden of disease and adaptation to life in patients with Crohn\u2019s perianal fistula: a qualitative exploration. Health Qual Life Outcomes. 2020;18:370.","journal-title":"Health Qual Life Outcomes."},{"key":"8060_CR6","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.3748\/wjg.v27.i25.3693","volume":"27","author":"A Vasudevan","year":"2021","unstructured":"Vasudevan A, Bruining DH, Loftus EV, Faubion W, Ehman EC, Raffals L. Approach to medical therapy in perianal Crohn\u2019s disease. World J. Gastroenterol. 2021;27:3693\u20133704.","journal-title":"World J. Gastroenterol."},{"key":"8060_CR7","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N. Engl. J. Med. 1999;340:1398\u20131405.","journal-title":"N. Engl. J. Med."},{"key":"8060_CR8","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/gut.2008.159251","volume":"58","author":"J-F Colombel","year":"2009","unstructured":"Colombel J-F, Schwartz DA, Sandborn WJ et al. Adalimumab for the treatment of fistulas in patients with Crohn\u2019s disease. Gut. 2009;58:940\u2013948.","journal-title":"Gut."},{"key":"8060_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in crohn\u2019s disease: the CLASSIC-I Trial. Gastroenterology. 2006;130:323\u2013333.","journal-title":"Gastroenterology."},{"key":"8060_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","volume":"146","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 2007;146:829\u2013838.","journal-title":"Ann. Intern. Med."},{"key":"8060_CR11","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1053\/j.gastro.2021.04.023","volume":"160","author":"S Singh","year":"2021","unstructured":"Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease. Gastroenterology. 2021;160:2512-2556.e2519.","journal-title":"Gastroenterology."},{"key":"8060_CR12","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.gastro.2003.08.025","volume":"125","author":"WJ Sandborn","year":"2003","unstructured":"Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn\u2019s disease. Gastroenterology. 2003;125:1508\u20131530.","journal-title":"Gastroenterology."},{"key":"8060_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5217\/ir.2017.15.2.182","volume":"15","author":"C-C Ji","year":"2017","unstructured":"Ji C-C, Takano S. Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn\u2019s disease. Intest Res 2017;15:182\u2013186.","journal-title":"Intest Res"},{"key":"8060_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/apt.13083","volume":"41","author":"JP Gisbert","year":"2015","unstructured":"Gisbert JP, Mar\u00edn AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment. Pharmacol. Ther. 2015;41:613\u2013623.","journal-title":"Aliment. Pharmacol. Ther."},{"key":"8060_CR15","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.3748\/wjg.15.4263","volume":"15","author":"C Taxonera","year":"2009","unstructured":"Taxonera C, Schwartz DA, Garc\u00eda-Olmo D. Emerging treatments for complex perianal fistula in Crohn\u2019s disease. World J. Gastroenterol. 2009;15:4263\u20134272.","journal-title":"World J. Gastroenterol."},{"key":"8060_CR16","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N. Engl. J. Med. 2004;350:876\u2013885.","journal-title":"N. Engl. J. Med."},{"key":"8060_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132:52\u201365.","journal-title":"Gastroenterology."},{"key":"8060_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/MCG.0000000000000169","volume":"49","author":"C Casta\u00f1o-Milla","year":"2015","unstructured":"Casta\u00f1o-Milla C, Chaparro M, Saro C et al. Effectiveness of adalimumab in perianal fistulas in crohn\u2019s disease patients naive to anti-TNF therapy. J. Clin. Gastroenterol. 2015;49:34\u201340.","journal-title":"J. Clin. Gastroenterol."},{"key":"8060_CR19","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.cgh.2021.07.053","volume":"20","author":"M De Gregorio","year":"2022","unstructured":"De Gregorio M, Lee T, Krishnaprasad K et al. Higher anti-tumor necrosis factor-\u03b1 levels correlate with improved radiologic outcomes in Crohn\u2019s perianal fistulas. Clin. Gastroenterol. Hepatol. 2022;20:1306\u20131314.","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"8060_CR20","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.3748\/wjg.v28.i23.2597","volume":"28","author":"B Gu","year":"2022","unstructured":"Gu B, Venkatesh K, Williams AJ et al. Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn\u2019s disease. World J. Gastroenterol. 2022;28:2597\u20132608.","journal-title":"World J. Gastroenterol."},{"key":"8060_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/00365521.2019.1600014","volume":"54","author":"AS Strik","year":"2019","unstructured":"Strik AS, L\u00f6wenberg M, Buskens CJ et al. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn\u2019s disease patients. Scand. J. Gastroenterol. 2019;54:453\u2013458.","journal-title":"Scand. J. Gastroenterol."},{"key":"8060_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/MEG.0000000000001561","volume":"32","author":"N Plevris","year":"2020","unstructured":"Plevris N, Jenkinson PW, Arnott ID, Jones GR, Lees CW. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn\u2019s disease. Eur. J. Gastroenterol. Hepatol. 2020;32:32\u201337.","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"8060_CR23","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.cgh.2012.12.042","volume":"11","author":"G Bouguen","year":"2013","unstructured":"Bouguen G, Siproudhis L, Gizard E et al. Long-term outcome of perianal fistulizing crohn\u2019s disease treated with infliximab. Clin. Gastroenterol. Hepatol. 2013;11:975-981.e974.","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"8060_CR24","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1007\/s10620-020-06398-w","volume":"66","author":"M Zhu","year":"2021","unstructured":"Zhu M, Xu X, Feng Q et al. Effectiveness of infliximab on deep radiological remission in Chinese patients with perianal fistulizing Crohn\u2019s disease. Dig. Dis. Sci. 2021;66:1658\u20131668.","journal-title":"Dig. Dis. Sci."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08060-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-023-08060-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08060-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T02:04:05Z","timestamp":1695434645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-023-08060-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["8060"],"URL":"https:\/\/doi.org\/10.1007\/s10620-023-08060-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"19 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors of this study have no financial disclosures or conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Boards of Johns Hopkins University and the University of California, Los Angeles (UCLA).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}